NCT00992446 2020-03-18
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
Clinical Trials
9 trialsNCT02208037 2019-01-23
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT00038571 2018-10-31
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00169468 2018-08-23
Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma
Lymphoma Study Association
Phase 2 Completed
NCT00634179 2016-10-27
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Emory University
Phase 1/2 Completed
NCT00379574 2013-03-15
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Asan Medical Center
Phase 1/2 Completed
NCT00054665 2012-09-11
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00312845 2012-06-25
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00085696 2008-02-11
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed